Prognostic Value of the MAGNIMS Score and its Application in Clinical Outcome Assessment of Disease Modifying Therapy in Patients with Relapsing Multiple Sclerosis: Results from the OPTIMUM Study of Ponesimod

被引：0
|
作者：
Keenan, A. [1 ]
Gandhi, K. [1 ]
Le, H. H. [1 ]
Turkoz, I. [1 ]
Guo, S. [2 ]
Liao, W.
Pelligra, C. G. [3 ]
机构：
[1] Janssen Pharmaceut, Titusville, NJ USA
[2] Evidera, Waltham, MA USA
[3] Evidera, Bogota, Colombia
来源：
MULTIPLE SCLEROSIS JOURNAL | 2022年 / 28卷 / 1_SUPPL期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P085
引用
收藏
页码：58 / 58
页数：1
相关论文
共 50 条
  • [21] Update on Safety Results from Patients with Exposure of up to 5 Years in an Ongoing Phase 3 Long Term Extension Study of Ponesimod in Relapsing Multiple Sclerosis
    Rosas-Ballina, M.
    Raghavan, N.
    Ait-Tihyaty, M.
    Vaclavkova, A.
    Sidorenko, T.
    Montalban, X.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 61 - 62
  • [22] Safety and Tolerability of Ponesimod Compared to Teriflunomide in Patients with Relapsing Multiple Sclerosis: Results of the Randomized, Active-Controlled, Double-Blind, Parallel-Group Phase 3 OPTIMUM Study
    Sprenger, Till
    Burcklen, Michel
    Freedman, Mark S.
    Fox, Robert
    Havrdova, Eva K.
    Hennessy, Brian
    Hohlfeld, Reinhard
    Lublin, Fred
    Montalban, Xavier
    Pozzilli, Carlo
    Vaclavkova, Andrea
    Scherz, Tatiana
    Linscheid, Philippe
    Pirozek-Lawniczek, Magdalena
    Kracker, Hilke
    Kappos, Ludwig
    NEUROLOGY, 2020, 94 (15)
  • [23] Efficacy and safety of ponesimod compared to teriflunomide in patients with relapsing multiple sclerosis: results of the randomized, active-controlled, double-blind, parallel-group phase 3 OPTIMUM study
    Kappos, L.
    Burcklen, M.
    Freedman, M. S.
    Fox, R.
    Havrdova, E. K.
    Hennessy, B.
    Hohlfeld, R.
    Lublin, F.
    Montalban, X.
    Pozzilli, C.
    Scherz, T.
    Linscheid, P.
    Pirozek-Lawniczek, M.
    Kracker, H.
    Sprenger, T.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 30 - 31
  • [24] Five-year study of adherence to disease-modifying therapies in patients with relapsing multiple sclerosis: 2-year interim results
    Ramo, C.
    Arroyo, E.
    Sanchez-Solino, O.
    JOURNAL OF NEUROLOGY, 2009, 256 : S125 - S125
  • [25] Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials
    Ziemssen, Tjalf
    Arnold, Douglas L.
    Alvarez, Enrique
    Cross, Anne H.
    Willi, Roman
    Li, Bingbing
    Kukkaro, Petra
    Kropshofer, Harald
    Ramanathan, Krishnan
    Merschhemke, Martin
    Kieseier, Bernd
    Su, Wendy
    Haering, Dieter A.
    Hauser, Stephen L.
    Kappos, Ludwig
    Kuhle, Jens
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [26] Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study
    Patti, F.
    Amato, M. P.
    Trojano, M.
    Bastianello, S.
    Tola, M. R.
    Goretti, B.
    Caniatti, L.
    Di Monte, E.
    Ferrazza, P.
    Morra, V. Brescia
    Lo Fermo, S.
    Picconi, O.
    Luccichenti, G.
    MULTIPLE SCLEROSIS JOURNAL, 2009, 15 (07) : 779 - 788
  • [27] KAIROS: A non-interventional study of ofatumumab in patients with relapsing remitting multiple sclerosis who previously received another disease-modifying therapy
    Bischof, Felix
    Groth, Marie
    Redolfi, Josef
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 1013 - 1013
  • [28] Evaluating the safety and tolerability of conversion to siponimod from disease-modifying therapies in patients with relapsing forms of Multiple sclerosis: the EXCHANGE study design
    Alvarez, E.
    Bar-or, A.
    Buckle, G. J.
    Cohan, S.
    Cree, B.
    Mao-Draayer, Y.
    McCarthy, M.
    Miller, A.
    Weinstock-Guttman, B.
    Jaitly, N.
    Cruz, L-A.
    Kolodny, S.
    Meng, X.
    Tomic, D.
    Su, W.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 472 - 472
  • [29] Pregnancy Outcomes in Patients With Ulcerative Colitis, Crohn's Disease, and Relapsing Multiple Sclerosis: Results From the Ozanimod Clinical Development Program
    Dubinsky, Marla C.
    Charles, Lorna
    Selmaj, Krzysztof W.
    Comi, Giancarlo
    Krakovich, Anthony
    Rosen, Melissa
    Van Der Woude, C. Janneke
    Mahadevan, Uma
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (12S): : S2 - S3
  • [30] Effects of subcutaneous interferon beta on disease parameters and cognition in patients with early relapsing-remitting multiple sclerosis: Longitudinal clinical and cognitive results from the COGIMUS (COGnition impairment in MUltiple sclerosis) study
    Patti, Francesco
    Amato, Maria Pia
    Tola, Maria Rosalia
    Trojano, Maria
    Ferrazza, Paolo
    Lijoi, Anrea Fausto
    Bastianello, Stefano
    NEUROLOGY, 2008, 70 (11) : A87 - A87
12345